1.
Serum magnesium levels and lung cancer risk: a meta-analysis.
Song, X, Zhong, X, Tang, K, Wu, G, Jiang, Y
World journal of surgical oncology. 2018;(1):137
Abstract
BACKGROUND Whether serum magnesium levels were lower in patients with lung cancer than that in healthy controls is controversial. The aim of this study was to identify and synthesize all citations evaluating the relationship between serum magnesium levels and lung cancer. METHODS We searched PubMed, WanFang, China National Knowledge Internet (CNKI), and SinoMed databases for relevant studies before December 31, 2017. Two authors independently selected studies, extracted data, and assessed risk of bias. RESULTS Eleven citations comprising 707 cases with lung cancer and 7595 healthy controls were included in our study. Serum magnesium levels were not significantly lower in patients with lung cancer [summary SMD = 0.193, 95%CI = - 1.504 to 1.890] when compared to health controls, with significant heterogeneity (I2 = 99.6%, P < 0.001) found. Negative associations were found among Asian populations [summary SMD = 0.229, 95%CI = - 1.637 to 2.094] and European populations [summary SMD = - 0.168, 95%CI = - 0.482 to 0.147]. No publication bias was found using the test of Egger and funnel plot. CONCLUSIONS Our study suggested that serum magnesium levels had no significant association on lung cancer risk.
2.
Effects of sequential chemotherapy of FOLFIRI/FOLFOX on the endocrine axes of ACTH-cortisol and renin-angiotensin-aldosterone.
Huang, C, Jiang, Y, Duan, G, Li, Z, Chen, L, Wang, X
Journal of neuro-oncology. 2012;(3):485-90
Abstract
The chemotherapies of FOLFOX (leucovorin + 5-fluorouracil + oxaliplatin) and FOLFIRI (folinic acid + 5-fluorouracil + irinotecan) are effective for a variety of malignant tumors. In particular, the sequential chemotherapy of FOLFOX/FOLFIRI has become the preferred post-operational treatment approach for gastrointestinal cancer and an important palliative care program for advanced cancer. However, the sequential chemotherapy of FOLFOX/FOLFIRI showed severe side effects due to the fact that the toxicity of the drugs can be enhanced by each other. Here, we report the dynamic changes in the activities of serum ACTH, cortisol, renin, angiotensin, and aldosterone in patients following multiple cycles of FOLFOX/FOLFIRI sequential chemotherapy. We found that the sequential chemotherapy might cause damage to the activities of the endocrine cells and/or the sympathetic nerve, and alter endocrine function, specifically the ACTH-cortisol and renin-angiotensin-aldosterone axes.